For years, the quantified self movement has left a critical gap in its dashboard. While wearables track steps, heart rate, and sleep with clinical precision, the data around menstrual cycles has remained stubbornly subjective, reliant on user-logged symptoms and estimates. Jenny Button noticed this during the COVID-19 lockdown, while wearing both an Oura ring and a Whoop band. The insight that followed,that a fundamental aspect of health for half the population was being measured with a calendar and a guess,became the founding premise for Emm [TechCrunch, November 2025].
Now, after five years of development and a $9 million seed round, the Bristol-based startup is preparing to launch what it calls the world's first smart menstrual cup. It is a hardware bet in a software-saturated health tracking space, embedding ultra-thin biosensors into a reusable, medical-grade silicone cup to measure flow volume, cycle length, and regularity in real time [SeedCue, November 2025]. The data syncs to a companion app, promising to turn a routine product of menstrual care into a diagnostic-grade biosensor. For founder and CEO Button, the goal is to move reproductive health monitoring from anecdote to algorithm.
The Hardware Wedge Into Femtech
Emm's fundamental bet is that subjective logging is insufficient. Existing cycle-tracking apps are powerful tools for pattern recognition, but they depend on users accurately recalling and entering symptoms like cramping or flow intensity. The smart cup, by contrast, is designed to collect objective, passive data on the volume and timing of menstrual flow itself. The company claims its sensors can establish a personal baseline within three cycles, enabling the app to highlight deviations that could signal underlying conditions like endometriosis, polycystic ovary syndrome (PCOS), or menorrhagia [SeedCue, November 2025].
The product itself is engineered for a specific, intimate use case. It offers up to 12 hours of protection and is designed to charge between cycles, aiming to fit seamlessly into existing routines [Perplexity Sonar]. The clinical and commercial ambition, however, stretches far beyond consumer convenience. Objective flow data represents a new dataset for clinical research in reproductive health, an area historically underfunded and lacking in quantitative biomarkers.
A Seed Round Built on Wearables Credibility
The $9 million seed round, closed in November 2025 and led by Lunar Ventures, signals strong investor belief in this hardware approach. Notably, the cap table includes strategic angels from the wearable health world, a clear vote of confidence in Emm's technical and commercial path.
Seed Round (Nov 2025) | 9 | M USD
Key investors include:
- Labcorp Venture Fund, the corporate venture arm of the global laboratory giant, suggesting a future channel for clinical validation and research partnerships.
- Harpreet Rai, the former CEO of Oura, who brings direct experience in scaling a sensor-based health wearable from niche to mainstream.
- Vivek Garipalli, founder of Clover Health, and Amar Shah, co-founder of AI company Wayve [TechCrunch, November 2025].
This blend of healthtech operators and deep-tech investors underscores the dual narrative: Emm is both a sophisticated hardware engineering challenge and a potential gateway into a vast, data-poor area of medicine.
The Team and the Long Road to Launch
Button has built a team that reflects the product's hybrid nature. Chris van Kempen, listed as Chief Design Officer, brings a user-experience focus critical for a sensitive consumer health device. The company has also hired a VP of Product, a Clinical Research and Partnerships Manager with a PhD, and a Senior Electronics Engineer, indicating a focus on both the sensor technology and the necessary clinical groundwork [emm.co].
The development timeline itself is a testament to the complexity. Button spent five years iterating through thousands of designs and conducting extended user testing before arriving at the current product [SeedCue, November 2025]. This lengthy gestation period, while indicative of rigorous development, also highlights the formidable barriers to entry in regulated bio-wearables that come into contact with bodily fluids. The company is currently in a pre-launch phase, with a waitlist open and a UK rollout targeted for early 2026, followed by a US entry in 2027 [TechCrunch, November 2025].
Navigating the Inevitable Headwinds
For all its promise, Emm's path is lined with challenges familiar to health hardware pioneers. The company must successfully navigate a gauntlet of regulatory, commercial, and privacy hurdles before its data can be taken seriously by users or clinicians.
- Regulatory classification. As a device that collects health data, it will likely need clearance as a Class I or II medical device in key markets like the UK, EU, and US. This process is non-trivial and time-consuming.
- Clinical validation. Investor interest is one thing; clinical trust is another. For the data to be used in care pathways or research, Emm will need to conduct and publish peer-reviewed studies demonstrating the accuracy and clinical utility of its metrics.
- Consumer privacy and trust. Handling intimate physiological data requires impeccable security and transparent data governance. Any misstep here could be fatal for a brand in this category.
- Market adoption. The product asks users to switch from established menstrual products to a higher-tech, likely higher-priced alternative. Its success hinges on proving the value of the data is worth the change in behavior and cost.
The company's answer to these risks appears to be its methodical pace, its clinical hires, and its investor base. The involvement of Labcorp and seasoned healthtech angels suggests a strategy aligned with long-term medical credibility, not just a fast consumer gadget launch.
The Patient Population and Standard of Care
The ultimate test for Emm will be its impact on the lived experience of menstrual health. The patient population here is vast: anyone who menstruates, but particularly those for whom cycle abnormalities are a source of pain, uncertainty, or diagnostic delay. Conditions like endometriosis take an average of seven to ten years to diagnose, often because symptoms are dismissed and objective measures are scarce.
The current standard of care for investigating heavy or irregular bleeding often involves patient diaries, ultrasound, and sometimes invasive procedures like hysteroscopy. It is a reactive, often delayed process. If Emm's cup can provide reliable, longitudinal data that a person can bring to their clinician, it could shift the paradigm toward earlier intervention and more data-informed conversations. That is the humane promise beneath the sensor technology,not just more data, but better, faster care.
For now, the focus is on the launch. The next twelve months will be critical. The company must translate its waitlist into a successful UK commercial launch, initiate the regulatory processes for its next markets, and likely begin the clinical studies that will determine whether this smart cup becomes a novel health tool or remains a niche consumer gadget. The $9 million seed round bought the runway; the coming year will reveal if the data holds up.
Sources
- [TechCrunch, November 2025] Emm raises $9M seed to create one of the world's first smart menstrual cups | https://techcrunch.com/2025/11/18/emm-raises-9m-seed-to-create-to-launch-one-of-the-worlds-first-smart-menstrual-cups/
- [SeedCue, November 2025] Emm raises over $9 million to launch world's first smart menstrual solution | https://www.seedcue.com/post/emm-raises-over-9-million-to-launch-worlds-first-smart-menstrual-solution
- [Perplexity Sonar] Research brief on Emm product specifications
- [emm.co] Company team page | https://www.emm.co/about